Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about a hair loss treatment regimen that does not include finasteride. Specific treatments used are not mentioned.

Exosomes are being considered for hair regrowth after using finasteride and minoxidil, with skepticism about their effectiveness and high cost. Users discuss administration methods like injections and microneedling, but concerns about pricing and potential scams are prevalent.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

Despite using treatments like Dutasteride, Minoxidil, RU58841, and GHK-Cu injections, the individual continues to experience aggressive hair thinning and is seeking a specialist for further help. Suggestions include trying finasteride, dermarolling, or another hair transplant.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.

Hair loss treatments discussed include minoxidil, finasteride, dutasteride RU, derma rolling, pyrilutamide, cosmeRNA, hair systems, and essential oils. The user seeks information on additional treatments, safety profiles, and alternative options for androgenetic alopecia.

PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.

The user is exploring hair growth stimulants other than Minoxidil, mentioning Stemoxydine, various peptides, drugs like Latanoprost and Bimatoprost, and natural remedies such as Rosemary Oil and Caffeine. They express concerns about the long-term effectiveness and safety of these alternatives and seek more information on viable options for hair regrowth.

Diffuse thinners often experience more hair regrowth with DHT blockers like finasteride, possibly due to less DHT sensitivity and the presence of miniaturized, not completely bald, follicles. However, regrowth varies widely among individuals, influenced by factors like genetics, the stage of hair loss, and treatment methods such as minoxidil, microneedling, and dermarolling.

Some individuals experience side effects from 5AR inhibitors like finasteride and are considering hair transplants without these medications, with some opting for surgeons like Dr. Zarev. Others are exploring alternative treatments and waiting for new medications in development, while some discuss managing side effects through lifestyle changes or additional medications.

Users discussed the effectiveness of Everychem's solution, similar to PP405, with some reporting improved hair thickness and new growth. Concerns were raised about safety and the legitimacy of the product, with some users advising against purchasing research chemicals.

A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.

User considers trying RU58841 for hair loss and asks for advice on its effectiveness and application. Responses vary, with some reporting positive results and others warning about potential risks or lack of change.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.

Finasteride and dutasteride are discussed for hair loss, with concerns about their effects on neurosteroids and potential side effects like depression. Alternatives like topical estrogen and lifestyle changes are considered, with varying opinions on mental health and hair regrowth.

The conversation discusses the effectiveness of topical Rapamycin for hair regrowth and color restoration. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

The user plans to test for DHT, total testosterone, free testosterone, E2, SHBG, and prolactin while supplementing with vitamin D and monitoring ferritin levels. They are experiencing hairline thinning and are seeking advice on whether their approach is excessive or lacking.

Prolactin and cortisol are identified as key factors in hair loss, with stress hormones impacting hair shedding. Finasteride and minoxidil are effective treatments, while DHT's role and individual sensitivity are significant factors.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

The conversation discusses using a violet ray device for hair regrowth, citing a case where zinc ion treatments showed promising results. It also mentions similar devices like the Growcombr and niostem helmet.

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Concerns are raised about the lack of studies on RU58841 and its potential effects.

Hair loss treatments Cosmerna, RU, and Pyri discussed. Cosmerna inhibits androgen receptors, but not 100%, so RU/Pyri can be used synergistically.

The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

The conversation is about someone planning to use cb-03-01 for hair loss because they experience side effects with other treatments like finasteride, minoxidil, and RU58841. They have not found progress pictures online and are considering sharing their own experience with cb-03-01, which is expensive.